CN106038904B - Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof - Google Patents
Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof Download PDFInfo
- Publication number
- CN106038904B CN106038904B CN201610387094.1A CN201610387094A CN106038904B CN 106038904 B CN106038904 B CN 106038904B CN 201610387094 A CN201610387094 A CN 201610387094A CN 106038904 B CN106038904 B CN 106038904B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- granule
- water
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 93
- 241001571764 Lysimachia christinae Species 0.000 title description 14
- 239000008202 granule composition Substances 0.000 title description 4
- 239000008187 granular material Substances 0.000 claims abstract description 114
- 239000000463 material Substances 0.000 claims abstract description 45
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 30
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 30
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 21
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 20
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 20
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 20
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 20
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 20
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 16
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 16
- 241000522190 Desmodium Species 0.000 claims abstract description 11
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 48
- 239000000284 extract Substances 0.000 claims description 47
- 238000001914 filtration Methods 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 32
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 31
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 17
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 239000000811 xylitol Substances 0.000 claims description 17
- 235000010447 xylitol Nutrition 0.000 claims description 17
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 17
- 229960002675 xylitol Drugs 0.000 claims description 17
- 239000004375 Dextrin Substances 0.000 claims description 16
- 229920001353 Dextrin Polymers 0.000 claims description 16
- 238000005520 cutting process Methods 0.000 claims description 16
- 235000019425 dextrin Nutrition 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 description 80
- 210000004185 liver Anatomy 0.000 description 40
- 230000036407 pain Effects 0.000 description 31
- 208000002193 Pain Diseases 0.000 description 30
- 239000000341 volatile oil Substances 0.000 description 30
- 241000632227 Antenoron Species 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 230000006870 function Effects 0.000 description 28
- 210000000232 gallbladder Anatomy 0.000 description 28
- 241000283973 Oryctolagus cuniculus Species 0.000 description 27
- 244000150195 Cyperus longus Species 0.000 description 26
- 210000000941 bile Anatomy 0.000 description 26
- 230000001737 promoting effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 201000001883 cholelithiasis Diseases 0.000 description 24
- 241000245665 Taraxacum Species 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 22
- 244000075634 Cyperus rotundus Species 0.000 description 18
- 235000016854 Cyperus rotundus Nutrition 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 208000004880 Polyuria Diseases 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 241000092668 Artemisia capillaris Species 0.000 description 14
- 235000008658 Artemisia capillaris Nutrition 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 240000007164 Salvia officinalis Species 0.000 description 13
- 210000000683 abdominal cavity Anatomy 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 206010023126 Jaundice Diseases 0.000 description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 235000005412 red sage Nutrition 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 11
- 206010042674 Swelling Diseases 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 11
- 230000001603 reducing effect Effects 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 241000202726 Bupleurum Species 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000035619 diuresis Effects 0.000 description 10
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 description 9
- 244000236521 Bupleurum rotundifolium Species 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 240000001341 Reynoutria japonica Species 0.000 description 9
- 235000018167 Reynoutria japonica Nutrition 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000001882 diuretic effect Effects 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001198 duodenum Anatomy 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000005875 quercetin Nutrition 0.000 description 6
- 229960001285 quercetin Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 206010007027 Calculus urinary Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000019255 Menstrual disease Diseases 0.000 description 5
- 208000009911 Urinary Calculi Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- RTBLDXVIGWSICW-JMSVASOKSA-N (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-ene Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)CC[C@]13C2(C)C RTBLDXVIGWSICW-JMSVASOKSA-N 0.000 description 4
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
- 241000612166 Lysimachia Species 0.000 description 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 241000292546 Taraxacum mongolicum Species 0.000 description 4
- 208000037386 Typhoid Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000001352 cholecystitis Diseases 0.000 description 4
- 230000001989 choleretic effect Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
- 229960002646 scopolamine Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 201000008297 typhoid fever Diseases 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010004637 Bile duct stone Diseases 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241001164374 Calyx Species 0.000 description 3
- 244000201986 Cassia tora Species 0.000 description 3
- 235000014552 Cassia tora Nutrition 0.000 description 3
- 201000009331 Choledocholithiasis Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000320571 Cymbidium floribundum Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 235000011158 Prunus mume Nutrition 0.000 description 3
- 244000018795 Prunus mume Species 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 241000607764 Shigella dysenteriae Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 3
- -1 anthraquinone compounds Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 208000003167 cholangitis Diseases 0.000 description 3
- 238000002192 cholecystectomy Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- ZZBWSNKBZKPGAK-UHFFFAOYSA-N chrysophanol-9-anthrone Chemical compound C1=CC=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O ZZBWSNKBZKPGAK-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000001543 purgative effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- KUFXJZXMWHNCEH-DOMZBBRYSA-N (4as,7r)-1,4a-dimethyl-7-prop-1-en-2-yl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1CC(=O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C KUFXJZXMWHNCEH-DOMZBBRYSA-N 0.000 description 2
- YOVSPTNQHMDJAG-UHFFFAOYSA-N (5ξ,7ξ,10ξ)-eudesma-4(14),11-diene Chemical compound C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- CEHVTERMWMYLCP-UHFFFAOYSA-N 1-(hydroxymethyl)-6,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound C1=2OC=C(CO)C=2C(=O)C(=O)C2=C1C=CC1=C2CCCC1(C)C CEHVTERMWMYLCP-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 241001388119 Anisotremus surinamensis Species 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 241000587240 Cynanchum Species 0.000 description 2
- RTBLDXVIGWSICW-UHFFFAOYSA-N Cyperene Chemical compound CC1CCC2CC3=C(C)CCC13C2(C)C RTBLDXVIGWSICW-UHFFFAOYSA-N 0.000 description 2
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 240000001972 Gardenia jasminoides Species 0.000 description 2
- 241000717671 Glechoma longituba Species 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010023138 Jaundice neonatal Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000893976 Nannizzia gypsea Species 0.000 description 2
- 201000006346 Neonatal Jaundice Diseases 0.000 description 2
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 2
- 206010037597 Pyelonephritis acute Diseases 0.000 description 2
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 2
- 206010038084 Rectocele Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000329195 Sparganium erectum Species 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 235000014364 Trapa natans Nutrition 0.000 description 2
- 240000001085 Trapa natans Species 0.000 description 2
- 241000893966 Trichophyton verrucosum Species 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 201000005661 acute cystitis Diseases 0.000 description 2
- 201000001555 acute pyelonephritis Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 208000027687 belching Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 201000006368 chronic pyelonephritis Diseases 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 229930192014 saikosaponin Natural products 0.000 description 2
- 235000009165 saligot Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- KFQRJXIFGJGHTO-UHFFFAOYSA-N 4-methoxycyclohexa-3,5-diene-1,2-dione Chemical compound COC1=CC(=O)C(=O)C=C1 KFQRJXIFGJGHTO-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010049589 Afterbirth pain Diseases 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 241001249165 Artemisia nova Species 0.000 description 1
- 235000003069 Artemisia scoparia Nutrition 0.000 description 1
- 241001249148 Artemisia scoparia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000510654 Bupleurum chinense Species 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 235000001948 Cassia occidentalis Nutrition 0.000 description 1
- 244000062995 Cassia occidentalis Species 0.000 description 1
- 241000723422 Catalpa Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- FYBLWUVZITWWEZ-UHFFFAOYSA-N Cl.[Ca] Chemical compound Cl.[Ca] FYBLWUVZITWWEZ-UHFFFAOYSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 244000227573 Desmodium styracifolium Species 0.000 description 1
- 241000175995 Dichondra Species 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000709714 Echovirus E11 Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017631 Gallbladder fistula Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000159512 Geotrichum Species 0.000 description 1
- 235000014043 Glechoma hederacea var parviflora Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001354532 Holozonia filipes Species 0.000 description 1
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001598107 Imperata Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 241000827125 Lupinus flavoculatus Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- UBUCNCOMADRQHX-UHFFFAOYSA-N N-Nitrosodiphenylamine Chemical compound C=1C=CC=CC=1N(N=O)C1=CC=CC=C1 UBUCNCOMADRQHX-UHFFFAOYSA-N 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 244000215554 Nepeta hederacea Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 241000270714 Persicaria japonica Species 0.000 description 1
- 241001254606 Peucedanum praeruptorum Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000064622 Physalis edulis Species 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001330502 Stephania Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 241001454294 Tetranychus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000874380 Zanthoxylum micranthum Species 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MGRRGKWPEVFJSH-UHFFFAOYSA-N dianthrone Natural products C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000000071 effect on fever Effects 0.000 description 1
- 230000000311 effect on hepatitis Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000002504 lithotomy Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000012186 ozocerite Substances 0.000 description 1
- 244000138993 panchioli Species 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000009916 yin-huang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a composition of jinqian dantong granules and a preparation method thereof. The granules are prepared from 10-1500 parts by weight of Glechomae herba, 10-1000 parts by weight of giant knotweed rhizome, 10-1000 parts by weight of dandelion, 10-1000 parts by weight of oriental wormwood, 10-1000 parts by weight of desmodium, 10-500 parts by weight of Salvia miltiorrhiza, 10-500 parts by weight of prepared rhizoma Cyperi, 10-500 parts by weight of radix bupleuri, 10-500 parts by weight of dark plum fruit and 10-500 parts by weight of semen cassiae, and appropriate auxiliary materials are added. The invention also relates to a preparation method of the Jinqian Dantong granules. The granule of the invention has excellent properties, for example, the granule of the invention has excellent stability.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, relates to a medicine, namely a granule composition for treating cholelithiasis and a preparation method thereof, and particularly relates to a granule composition for treating cholelithiasis and a preparation method thereof.
Background
Cholelithiasis is a common and frequently encountered disease in clinic, the incidence rate of the cholelithiasis in China is more than 10 percent, and the cholelithiasis is in a trend of rising year by year. The mechanism of cholelithiasis, which is not completely understood at present, is generally thought to be associated with infectious inflammation of the hepatobiliary system, changes in the composition, physicochemical properties, and hydrodynamics of bile. Recent studies have shown that changes in immune responses, immune complexes and expression of certain genes may also be involved in the formation of cholelithiasis. With the progress of the research, it is believed that the mechanism of cholelithiasis formation will be elucidated step by step. Clinically, the distribution of calculus at different parts in the biliary tract system can be divided into cholelithiasis and bile duct calculus (choledocholithiasis and hepatolithiasis); according to the chemical composition and appearance of calculus, it can be classified into cholesterol calculus and cholechrome calculus. Currently, the western medicine treatment of cholelithiasis is mainly non-operative treatment and operative treatment, wherein the non-operative treatment comprises oral cholecystectomy and lithotripsy, and the operative treatment mainly comprises cholecystectomy, laparoscopic cholecystectomy, choledocomy exploratory lithotomy, hepatectomy and the like. The effects achieved by the above-mentioned treatment methods to date are not yet satisfactory for clinical patients: the non-operative treatment can partially or completely dissolve the calculus formed by the patient in a short time, and then discharge or take out the calculus. But the treatment has small success rate and high cost (side effect, complication and high price), and can not radically solve the recurrence of the calculus. In addition, no ideal scheme is available for treating the bilirubin calculus. Secondly, although the calculus and the origin thereof can be removed more completely through the operation treatment, the operative complications are still high, and the bile duct calculus, particularly the intra-hepatic bile duct calculus treated through the operation treatment, still has high complications and mortality. In addition, long-term retention of calculus in the biliary tract can also cause canceration and secondary pancreatic and liver damage.
The prior published literature introduces a plurality of research results of treating urinary calculus and gallstone diseases by using longhairy antenoron herb or longhairy antenoron herb mixture, such as 1990, 13(6), 40-41 pharmacological research of longhairy antenoron herb granules, and research on the effects of treating urinary calculus and relieving pain by using longhairy antenoron herb granules; the 'jinqianlianlin oral liquid for treating urinary system infection' is observed in the curative effect of the oral liquid for treating urinary system infection (longhairy antenoron herb, herba pyrrosiae, spora lygodii, honeysuckle stem and lalang grass rhizome) (acute cystitis, acute pyelonephritis and acute attack of chronic pyelonephritis) in treating urinary system infection lower-jiao damp-heat type stranguria, namely acute cystitis, acute pyelonephritis and acute attack of chronic pyelonephritis; chinese patent application No. 200810043138.0, "a pharmaceutical composition for treating cholelithiasis", discloses a pharmaceutical composition for treating cholelithiasis, which is prepared from the following Chinese medicinal herbs (by weight ratio): 80 parts of prepared saltpeter, 35 parts of alum, 90 parts of turmeric root-tuber, 45 parts of common burreed rhizome, 45 parts of pig gall paste, 225 parts of longhairy antenoron herb, 150 parts of tangerine peel, 35 parts of prepared frankincense, 35 parts of prepared myrrh, 45 parts of rhubarb and 25 parts of liquorice; chinese patent application No. 200510200576.3 discloses a medicinal preparation for treating cholelithiasis and its preparation method, wherein the preparation is prepared from herba Lysimachiae 660g, herba Artemisiae Scopariae 660g, Scutellariae radix 198g, radix aucklandiae 198g, radix Curcumae 198g, radix et rhizoma Rhei 330g, Arecae semen 330g, fructus Aurantii Immaturus 132g parched with bran, refined Natrii sulfas 66g, and refined cortex Magnolia officinalis 132g by making into powder.
The traditional Chinese medicine does not have the name of cholelithiasis, but can be classified into the ranges of hypochondriac pain, choledistention, epigastric pain, jaundice and the like according to common symptoms of the cholelithiasis. Its description can be traced to the era of the "internal classic", such as the "som questions & muir theory" which: "pathogenic qi attacking the collaterals of foot shaoyang causing hypochondriac pain", as in Ling Shu & Jing Mai, recorded in the book: the pulse of shaoyang abdomen-foot is a pulse which causes bitter taste in mouth and fails to turn to the side, as in the cloud of Ling Shu-Dan Lun: "abdominal distension, distending pain in the hypochondrium, bitter taste in the mouth and good frequent sighing", clearly indicates the location of cholelithiasis, while the liver is below the hypochondrium and its meridians are distributed over the hypochondrium; the gallbladder is attached to the liver, and its pulse also circulates in the hypochondrium, and the liver and gallbladder are related to each other by the meridians of the meridians. Bile stored in the gallbladder comes from the residual qi of the liver, and the normal excretion and function of bile depends on the smoothing flow of the liver. If the liver fails to dredge, it will affect the secretion and excretion of bile; on the contrary, the smooth discharge of bile also affects the smoothing flow of liver. Is the close relation of the liver and the gallbladder in physiology and pathology, and determines the combined action of the two meridians of the liver and the gallbladder in the process of forming the cholelithiasis. Just as in chapter cloud of Jingyue quan shu hypochondriac pain: the hypochondriac pain is due to the two meridians of the liver and gallbladder, and the two meridians circulate along the hypochondriac region. The cause of cholelithiasis is not related to emotional disorder, improper diet and external infection of damp pathogen, and long-term emotional discomfort can lead to stagnation of liver-qi, dysfunction of smoothing flow, and obstruction of bile flow. Overeating, hunger and satiety, addiction to spicy food, fatness, thickness and greasiness, damage to spleen and stomach, dampness and heat generation, and bile decoction. Dampness in the lower part, improper living, cold-dampness or damp-heat affecting the transportation and transformation of the spleen and stomach, stagnation of wood and earth, and stagnation of gallbladder qi. All factors cause disorder of qi movement of liver and gallbladder, accumulation of damp-heat in the interior, and long-term decoction of bile to form gallstones, which can block biliary tract and further cause disorder of qi movement to further cause large gallstones. For the pathological analysis and syndrome classification of this disease, there are differences due to different medical treatment opinions and observation angles, and the common types include qi stagnation and blood stasis, damp-heat accumulation, liver and gallbladder yang deficiency, spleen deficiency and dampness accumulation, and liver and kidney yin deficiency. At present, there are three types of syndromes of qi stagnation, damp-heat and sepsis listed in the guideline of clinical research on new Chinese medicines issued by the Ministry of health of the people's republic of China. Obstruction of qi activity is easily caused by retention of damp-heat in the interior; heat accumulation does not dissipate, and heat toxicity transforms into fire, which becomes pus after decomposition, leading to sepsis. Clinically, the syndrome differentiation and the classification of cholelithiasis are still characterized by the syndrome of damp-heat, stagnation of damp-heat and uncomfortable qi and blood in channels and collaterals, so that the right upper abdomen is uncomfortable, even angina is intolerable, and the pain is led to the shoulders and the back; affecting the liver-gallbladder qi movement, and ascending of gallbladder qi, bitter taste in mouth and dry throat; when gallbladder qi flows transversely and reversely to the stomach, stomach qi fails to descend and fu-organs are obstructed, nausea, vomiting, acid regurgitation, frequent belching and constipation occur; when the damp-heat fumigates, bile will not overflow along the normal course, the eyes will be yellow or the eyes will be yellow, and when the damp-heat goes down the bladder, the urine will be yellow. Therefore, the clinical treatment of this disease is mainly to clear heat and promote diuresis, move qi and alleviate pain.
The art still expects the jindan tong granules with excellent performance.
Disclosure of Invention
The invention aims to provide the jinqian dantong granules with excellent performance for treating cholelithiasis and the preparation method thereof. The invention prepares the jindan tong granules by a unique formula, and unexpectedly finds that the obtained jindan tong granules have excellent performance. The present invention has been completed based on this finding.
Therefore, the invention provides a granule for treating choledocholithiasis, which is prepared from 10-1500 parts by weight of Glechomae herba, 10-1000 parts by weight of rhizoma Polygoni Cuspidati, 10-1000 parts by weight of herba Taraxaci, 10-1000 parts by weight of herba Artemisiae Scopariae, 10-1000 parts by weight of herba Lysimachiae Christinae, 10-500 parts by weight of Saviae Miltiorrhizae radix, 10-500 parts by weight of rhizoma Cyperi preparata, 10-500 parts by weight of bupleuri radix, 10-500 parts by weight of mume fructus, 10-500 parts by weight of semen Cassiae, and appropriate adjuvants.
The granule for treating cholangitis according to any one of the embodiments of the first aspect of the present invention is prepared from, by weight, 500-1000 parts of Glechomae herba, 300-450 parts of Polygonum cuspidatum, 300-450 parts of Taraxacum mongolicum, 450-700 parts of Artemisia capillaris, 450-700 parts of Lysimachia christinae Hance, 100-250 parts of Salvia miltiorrhiza, 100-250 parts of processed Cyperus rotundus L, 100-250 parts of radix bupleuri, 100-250 parts of Prunus mume, 100-250 parts of Cassia obtusifolia, and.
The granule for treating cholangitis according to any one of the embodiments of the first aspect of the present invention is prepared from 700-800 parts by weight of Glechomae herba, 350-400 parts by weight of Polygonum cuspidatum, 350-400 parts by weight of Taraxacum mongolicum, 500-600 parts by weight of Artemisia capillaris, 500-600 parts by weight of Lysimachia christinae Hance, 150-200 parts by weight of Salvia miltiorrhiza, 150-200 parts by weight of processed Cyperus rotundus, 150-200 parts by weight of radix bupleuri, 150-200 parts by weight of Prunus mume.
The granule for treating bile secretion is prepared from 750 parts of longhairy antenoron herb, 375 parts of giant knotweed rhizome, 375 parts of dandelion, 562.5 parts of oriental wormwood, 562.5 parts of longhairy antenoron herb, 187.5 parts of salvia miltiorrhiza, 187.5 parts of prepared nutgrass galingale rhizome, 187.5 parts of Chinese thorowax root, 187.5 parts of dark plum fruit and 187.5 parts of cassia seed by weight according to the weight components, and proper auxiliary materials are further added.
According to any one embodiment of the first aspect of the invention, each 1000g of the granule is prepared from 700-800 g of Glechomae herba, 350-400 g of rhizoma Polygoni Cuspidati, 350-400 g of herba Taraxaci, 500-600 g of herba Artemisiae Scopariae, 500-600 g of herba Lysimachiae, 150-200 g of Saviae Miltiorrhizae radix, 150-200 g of rhizoma Cyperi preparata, 150-200 g of bupleuri radix, 150-200 g of mume fructus, 150-200 g of semen Cassiae, and appropriate auxiliary materials.
According to any embodiment of the first aspect of the invention, the granules are prepared from 750g of Glechomae herba, 375g of rhizoma Polygoni Cuspidati, 375g of herba Taraxaci, 562.5g of herba Artemisiae Scopariae, 562.5g of herba Lysimachiae Christinae, 187.5g of Saviae Miltiorrhizae radix, 187.5g of rhizoma Cyperi preparata, 187.5g of bupleuri radix, 187.5g of mume fructus, 187.5g of semen Cassiae per 1000g, and appropriate adjuvants.
The desmodium cholangiolic granule according to any embodiment of the first aspect of the present invention, wherein the adjuvant is selected from the group consisting of: fillers, flavoring agents, and combinations thereof. In one embodiment, the bulking agent is dextrin; the amount thereof is usually adjusted empirically, for example added to a specified filling amount. In one embodiment, the flavoring agent is stevia; the amount is generally adjusted empirically and may generally be in the range 0.2% to 2%, for example 0.2% to 1%, for example 0.2% to 0.5%.
The jinqian dantong granules according to any one of the embodiments of the first aspect of the present invention, wherein the auxiliary material further comprises xylitol. In one embodiment, the xylitol comprises 1 to 5%, such as 1 to 3%, such as 2% of the total weight of the granule. It has been surprisingly found that when xylitol is added in small amounts to granules, it is possible to impart excellent moisture absorption-avoiding properties to the granules; however, it cannot be explained that this property is only obtained with the simultaneous addition of dextrin.
The granules according to any embodiment of the first aspect of the present invention are prepared according to a method comprising the steps of:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) adding 8-10 times of water into the Glechomae herba and the Lysimachia christinae Hance together, decocting and extracting for 1-3 hours, and filtering; adding 6-8 times of water into filter residues, decocting and extracting for 1-2 hours, and filtering; mixing the two filtrates for later use;
(3) adding 8-10 times of water into the other eight medicinal materials, decocting and extracting for 1-3 hours, and filtering; adding 6-8 times of water into filter residues, decocting and extracting for 1-2 hours, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
The granule for treating choledocholithiasis according to any one of the embodiments of the first aspect of the present invention, wherein in the step (2) of preparing the granule for treating choledochus pseudonanus, 0.2 to 1% of acetic acid, especially 0.2 to 0.5% of acetic acid is added to the extraction solvent water used. It has been surprisingly found that when both Glechomae herba and Lysimachiae herba are extracted together and a little acetic acid is added to the extraction solvent, unexpectedly superior effects are exhibited.
Further, the invention provides a method for preparing the desmodium and cholangiopsis granule, which comprises the following steps of 10-1500 parts by weight of desmodium, 10-1000 parts by weight of polygonum cuspidatum, 10-1000 parts by weight of dandelion, 10-1000 parts by weight of oriental wormwood, 10-1000 parts by weight of lysimachia, 10-500 parts by weight of salvia miltiorrhiza, 10-500 parts by weight of prepared rhizoma cyperi, 10-500 parts by weight of radix bupleuri, 10-500 parts by weight of dark plum and 10-500 parts by weight of semen cassiae, and proper auxiliary materials are added to prepare the desmodium and cholangiopsis granule; the method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) adding 8-10 times of water into the Glechomae herba and the Lysimachia christinae Hance together, decocting and extracting for 1-3 hours, and filtering; adding 6-8 times of water into filter residues, decocting and extracting for 1-2 hours, and filtering; mixing the two filtrates for later use;
(3) adding 8-10 times of water into the other eight medicinal materials, decocting and extracting for 1-3 hours, and filtering; adding 6-8 times of water into filter residues, decocting and extracting for 1-2 hours, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
The process according to any one of the embodiments of the second aspect of the present invention, wherein in step (2), the extraction solvent used is water to which 0.2 to 1% of acetic acid, particularly 0.2 to 0.5% of acetic acid, is added. It has been surprisingly found that when both Glechomae herba and Lysimachiae herba are extracted together and a little acetic acid is added to the extraction solvent, unexpectedly superior effects are exhibited.
According to the method of any one embodiment of the second aspect of the invention, the granule is prepared from 500-1000 parts by weight of longhairy antenoron herb, 300-450 parts by weight of giant knotweed rhizome, 300-450 parts by weight of dandelion, 450-700 parts by weight of oriental wormwood, 450-700 parts by weight of longhairy antenoron herb, 100-250 parts by weight of salvia miltiorrhiza, 100-250 parts by weight of prepared nutgrass galingale rhizome, 100-250 parts by weight of radix bupleuri, 100-250 parts by weight of dark plum fruit, 100-250 parts by weight of cassia seed and proper auxiliary materials.
According to the method of any one embodiment of the second aspect of the invention, the granule is prepared from 700-800 parts by weight of Glechomae herba, 350-400 parts by weight of Polygonum cuspidatum, 350-400 parts by weight of Taraxacum mongolicum, 500-600 parts by weight of Artemisia capillaris, 500-600 parts by weight of Lysimachia christinae Hance, 150-200 parts by weight of Salvia miltiorrhiza Bunge, 150-200 parts by weight of prepared Cyperus rotundus L, 150-200 parts by weight of radix bupleuri, 150-200 parts by weight of Prunus mume, 150-200.
According to the method of any embodiment of the second aspect of the invention, the granule is prepared from 750 parts of longhairy antenoron herb, 375 parts of giant knotweed rhizome, 375 parts of dandelion, 562.5 parts of oriental wormwood, 562.5 parts of desmodium, 187.5 parts of salvia miltiorrhiza, 187.5 parts of prepared nutgrass galingale rhizome, 187.5 parts of bupleurum, 187.5 parts of dark plum fruit and 187.5 parts of cassia seed by weight and proper auxiliary materials.
According to the method of any one embodiment of the second aspect of the invention, each 1000g of the granule is prepared from 700-800 g of Glechomae herba, 350-400 g of Polygonum cuspidatum, 350-400 g of dandelion, 500-600 g of Artemisia capillaris, 500-600 g of Lysimachia christinae Hance, 150-200 g of Salvia miltiorrhiza, 150-200 g of prepared Cyperus rotundus L, 150-200 g of radix bupleuri, 150-200 g of smoked plum, 150-200 g of semen Cassiae, and proper auxiliary materials.
According to the method of any one embodiment of the second aspect of the invention, each 1000g of the granule is prepared from 750g of Glechomae herba, 375g of rhizoma Polygoni Cuspidati, 375g of herba Taraxaci, 562.5g of herba Artemisiae Scopariae, 562.5g of herba Lysimachiae Christinae, 187.5g of Salvia miltiorrhiza Bunge, 187.5g of rhizoma Cyperi preparata, 187.5g of bupleuri radix, 187.5g of mume fructus, 187.5g of semen Cassiae, and appropriate adjuvants.
The method according to any embodiment of the second aspect of the invention, wherein the excipient is selected from the group consisting of: fillers, flavoring agents, and combinations thereof. In one embodiment, the bulking agent is dextrin; the amount thereof is usually adjusted empirically, for example added to a specified filling amount. In one embodiment, the flavoring agent is stevia; the amount is generally adjusted empirically and may generally be in the range 0.2% to 2%, for example 0.2% to 1%, for example 0.2% to 0.5%.
The method according to any embodiment of the second aspect of the invention, wherein said excipient further comprises xylitol. In one embodiment, the xylitol comprises 1 to 5%, such as 1 to 3%, such as 2% of the total weight of the granule. It has been surprisingly found that when xylitol is added in small amounts to granules, it is possible to impart excellent moisture absorption-avoiding properties to the granules; however, it cannot be explained that this property is only obtained with the simultaneous addition of dextrin.
The property of the granules to avoid moisture absorption can be characterized by the moisture absorption rate, the lower the moisture absorption rate, the better. The moisture absorption rate measuring method comprises the following steps: the granules were exposed to an environment of 25 ℃ and 75% humidity for 10 hours, and the hygroscopic weight before and after this treatment was measured, and the hygroscopic weight as a percentage of the initial weight of the granules was determined as the hygroscopic rate. The moisture absorption rates of all the granules obtained in production examples 1 to 13 were measured, and the results showed that the moisture absorption rate of 13 batches of granules obtained in production example 10 was in the range of 3 to 5%, for example, the moisture absorption rate of 1091# particles was 3.31%, showing satisfactory moisture absorption rate (generally, moisture absorption rate lower than 5% was satisfactory, and moisture absorption rate higher than 10% was unacceptable); the moisture absorption rates of all the granules obtained in preparation examples 1 to 9 and preparation examples 11 to 13 were within a range of 14 to 23%, and for example, the moisture absorption rates of the granules 91#, 1191#, and 1291# were 18.3%, 21.2%, and 16.7%, respectively, which was unacceptable. It is known that xylitol has a certain hygroscopicity, but the addition of a small amount of xylitol to the granules of the invention improves the hygroscopicity of the granules, which is not entirely explained by the prior art.
Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict. The invention is further described below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.
The invention is used hereinafter "test example 1: the method for detecting typical components in the preparation comprises the step of measuring 8 batches of granules obtained in preparation examples 1-8 and each batch of granules obtained in preparation examples 10-13 according to the preparation methods of preparation examples 1-8, wherein the content of the index in the granules is within the range of 1.2-1.7 mg/g, for example, the content of the index in the granules of preparation examples 1-5 is respectively lower than that of the granules obtained by adding acetic acid in preparation example 9 by more than 0.5mg/g, which shows that the extraction solvent added with acetic acid in the step (2) is very beneficial. It was even more surprising that the granules obtained in preparation 9 and the batches of granules obtained in preparations 10 to 13 by the procedure of adding acetic acid to the extraction solvent water according to the preparation of preparation 9 had more stable properties than the granules obtained by other methods; specifically, the present invention is used hereinafter "test example 2: the method for determining the stability of the granules comprises the steps of measuring that the residual percentage of the indicators in 8 batches of granules obtained in preparation examples 1-8 and each batch of granules obtained in preparation examples 10-13 by referring to the preparation methods of preparation examples 1-8 are within the range of 86.6-90.4%, for example, the residual percentage of the indicators in the granules of preparation examples 1-5 is more than 7% lower than that of the granules obtained by adding acetic acid in preparation example 9; the inventor of the present invention has long worked on the pharmaceutical technology, and it can be understood that the difference in the preparation method may result in higher extraction rate of some components in the Chinese medicinal composition, but it is totally unexpected that the preparation method will cause improvement of product stability. The stability characteristics described above are long-term storage effects of the product, and it is shown in the pharmacodynamic test of the last part of the present invention that granules prepared by a special process exhibit more excellent effects with respect to the instant state of the product, particularly with respect to the biological effects thereof.
Glechomae herba is dried aerial part of Glechoma longituba (Nakai) Kupr. Collected in spring to autumn, removed of impurities and dried in the sun. The whole plant of Glechomae herba is used as medicine. Pungent and slightly bitter in flavor and slightly cold in nature. It enters liver, kidney and bladder meridians. Has effects of promoting diuresis, treating stranguria, clearing away heat and toxic materials, removing blood stasis, and relieving swelling. It is used clinically in treating heat stranguria, urolithic stranguria, jaundice due to damp-heat pathogen, sore, carbuncle, swelling and pain, and traumatic injury. Glechomae herba has effects of promoting bile secretion of biliary cell, increasing bile in liver and gallbladder, increasing internal pressure, and relaxing biliary tract including calyx Seu fructus Physalis to discharge bile. Glechomae herba has diuretic effect, and the decoction has remarkable diuretic effect when administered by intragastric administration to rat, and the diuretic effect is gradually reduced when continuously applied. The experiment of the rabbit with the anesthetic alcohol also has obvious diuretic effect. Glechomae herba has calculus dissolving effect, and can change urine into acid, and dissolve calculus under alkaline condition. Glechomae herba has antibacterial test, and is extremely sensitive to Staphylococcus aureus, Bacillus dysenteriae in Song dynasty, and neither Escherichia coli, Pseudomonas aeruginosa nor Salmonella typhi.
Polygonum cuspidatum, also known as pseudo-Hemsleya amabilis, Tupistia chinensis, Panax notoginseng or Polygonum japonicum, is a plant of the Polygonaceae family. Polygonum cuspidatum, a perennial herb, is not high, but can also grow to 3 to 4 meters. The stem is node and hollow, just like a cane, with the addition of triangular leaves, the structure is very similar to a bamboo, but there is no relation between the two. The young leaves of polygonum cuspidatum all have red speckles. Male and female heterozygotes. Giant knotweed rhizome is produced in east Asia, and is distributed in the southwest area of the west of Hokkaido, Korea, Taiwan, Jiangsu, Jiangxi, Shandong, Sichuan and the like in China. Rhizoma Polygoni Cuspidati is used as medicine with dried rhizome and root. Rhizoma Polygoni Cuspidati has effects of promoting diuresis, eliminating jaundice, clearing heat and detoxicating, removing blood stasis, relieving pain, relieving cough and eliminating phlegm. The externally applied preparation is clinically used for damp-heat jaundice, stranguria with turbid discharge, leukorrhagia, rheumatic arthralgia, carbuncle, swelling, sore and toxin, scald caused by water and fire, amenorrhea, abdominal mass, injury from fuding and cough caused by lung heat. Recorded in Ben Cao gang mu, Hu Zhang powder is taken with wine to treat postpartum pain due to blood stasis and dizziness. Recorded in Ming Yi Bie Lu (famous physicians and miscellaneous records) that Hu Zhang is mainly used for treating menstrual bleeding and bleeding stagnation. Recorded in Dian nan materia Medica, Polygonum cuspidatum has the effects of eliminating various toxic swelling, relieving sore throat, promoting urination and dredging channels and collaterals. It is indicated for white turbidity of five kinds of stranguria, anal fistula, sores and abscess, and leucorrhea with reddish discharge of women.
Taraxacum mongolicum hand-Mazz, Compositae, Taraxacum perennial herbs. The root is cone-shaped, the surface is dark brown, the leaf is wrinkled, the edge of the leaf has wavy teeth or pinnate deep cleft sometimes, the base part is narrowed into a petiole, the petiole and the main pulse are often reddish purple, the upper part of the scape is purplish red, and the leaf is densely covered by spider-silk white long and soft hair; head-shaped inflorescence, general bud bell shape, dark brown lean fruit, white long-crown hair, and flower and fruit period of 4-10 months. Herba Violae, herba Veronicae Diversifoliae. It is called Hualang in south of the Yangtze river. Compositae is a perennial herb. The head-shaped inflorescence, the seeds are provided with pompon formed by white crown hairs, and the pompon floats to a new place along with wind after the flowers bloom to inoculate new life. The dandelion plant contains various health nutritional components such as taraxol, taraxacin, choline, organic acid, inulin, etc. Has diuretic, laxative, jaundice treating, and gallbladder promoting effects. The herba Taraxaci can be eaten raw, fried and used as soup, and is a plant used as both medicine and food. Dandelion is sweet in nature, slightly bitter in taste and cold in nature. Has the effects of clearing away heat and toxic materials, relieving swelling, and dispersing pathogenic accumulation. Clinically, it is usually used for clearing heat and removing toxicity, inducing diuresis and resolving masses. It can be used for treating acute mastitis, lymphadenitis, lymphoid tuberculosis, furunculosis, acute conjunctivitis, common cold with fever, acute tonsillitis, acute bronchitis, gastritis, hepatitis, cholecystitis, and urinary tract infection. The dandelion has strong bactericidal effect on staphylococcus aureus drug-resistant strains and hemolytic streptococcus. It also has antibacterial effect on Diplococcus pneumoniae, meningococcus, diphtheria bacillus, Pseudomonas aeruginosa, Shigella dysenteriae, typhoid bacillus, etc., and on Catalpa coccus. Alcohol extract of dandelion 1: 400 can inhibit tubercle bacillus, but decoction 1: 100 is not valid. The method comprises the following steps of 1: 80 can delay ECHO11 virus cytopathy, and the alcohol extract (31mg/kg) can kill leptospira and inhibit some fungi. Has good killing effect on helicobacter pylori. The dandelion leaves have the functions of dredging the obstruction of mammary vessels and promoting lactation. The polysaccharide (Tof-CFr) extracted from medicinal herba Taraxaci was administered to MM46 tumor cell-inoculated C3H mice at 40, 2, and 600mg/kg ip, and the former administration did not have effect, but the later administration at 11-20d and 2-20d in alternate days was effective. Delayed hypersensitivity to tumor cells (T-DHR), with Tof-CFr administered late, showed significantly higher plantar responses in both ddy-Ehrlich (syngeneic tumor) and C3H-MM46 (syngeneic tumor) lines compared to the control. In the ADMC line, Tof-CFr has a greater activation potential than glycogen known to activate macrophages. The dandelion has the function of benefiting gallbladder, and is clinically effective in treating chronic cholecystospasm and lithiasis. In addition, it has the actions of inducing diuresis, invigorating stomach, and alleviating diarrhea.
Oriental wormwood, Artemisia scoparia waldst.et Kit; latin name: artemisinia phillars thunb. Alias: herba Artemisiae Scopariae, herba Artemisiae Annuae, herba Artemisiae Anomalae, herba Lupuli, herba Veronicae Divaricati, and herba Artemisiae Annuae. Family genus: a food belonging to Compositae family. Yin Chen Hao is not dead in winter, while in spring it is grown from Chen root, so it is named Chen or Yin Chen. As the young plants become artemisia in summer, they are also called Yin Chen Hao. Herba Artemisiae Scopariae is cool in nature and bitter in flavor; entering liver meridian, spleen meridian and bladder meridian, has the effects of clearing heat and promoting diuresis, and is mainly used for damp-heat jaundice, cholecystitis, dysuria, wind itching, sore, scabies, eczema, pruritus and early damp-warm syndrome. It is combined with Zhi Zi, Da Huang for yang Huang, Fu Zi and gan Jiang for yin Huang. The oriental wormwood has obvious liver protection effect, has obvious curative effect on hepatitis A, hepatitis B and icteric hepatitis, is beneficial to gallbladder, promotes bile secretion, increases the discharge of cholic acid and bilirubin in the bile, can increase blood flow of coronary artery of heart, improves microcirculation, and has the effects of reducing blood pressure, reducing blood fat, resisting blood coagulation, inducing diuresis, relieving fever and asthma, expelling ascarid and inhibiting various pathogenic dermatophytes and bacteria. Blood fat reduction and atherosclerosis resistance: herba Artemisiae Scopariae can reduce serum cholesterol and beta-lipoprotein of hyperlipemia animals, obviously reduce cholesterol content in aortic wall, and relieve atherosclerotic plaque lesion. And (3) alleviating jaundice: being bitter and purging with descending, cold in nature and clearing heat, it excels in clearing damp-heat from spleen, stomach, liver and gallbladder, so it is the essential herb for jaundice. For yang-Huang syndrome due to yellow eyes and scanty and brownish urine, it is often combined with Zhi Zi, Huang Bai and Da Huang, such as Yin Chen Hao Tang (treatise on Cold-induced fever); for jaundice with damp-heat preference, it is combined with Fu Ling and Zhu Ling. And (3) tumor resistance: the herba Artemisiae Scopariae decoction has effects of inhibiting and killing mouse ehrlich ascites carcinoma cells and transplanted MethA cells, and can prolong survival time of tumor-bearing mice. The capillin chromone and thimerovin in the capillary artemisia have the obvious effect of inhibiting the proliferation of Hela cells and Ehrlich ascites cancer cells. In addition, the herba Artemisiae Scopariae decoction can remarkably inhibit the mutagenesis of carcinogen-aflatoxin B (AFBl). Therefore, the capillary artemisia can resist the tumor. Antipyretic and antimicrobial effects: the herba Artemisiae Scopariae decoction and herba Artemisiae Scopariae infusion have antipyretic effect on rabbit artificial fever. Herba Artemisiae Scopariae and its congeneric plant Artemisiatrident and volatile oil of A.nova, have obvious inhibitory effects on Staphylococcus aureus in test tube, and also have certain inhibitory effects on Bacillus dysenteriae, hemolytic streptococcus, Diplococcus pneumoniae, Dipteria diphtheriae, bovine and human type tubercle bacillus, etc. The herba Artemisiae Scopariae volatile oil can inhibit the growth of pathogenic fungi in test tube, and its antifungal component is capillin. Relieving itching and cooling: the herba artemisiae scopariae has good effects of clearing heat, relieving itching and refreshing, and the symptoms such as general wind itch, scalp itch and the like can be treated by adding a proper amount of decoction of the herba artemisiae scopariae into bath water for bathing. The function of gallbladder promotion: experiments show that the herba artemisiae scopariae decoction, the herba artemisiae scopariae gardenia decoction, the herba artemisiae scopariae decoction (the ratio of herba artemisiae scopariae to fructus gardeniae to rhubarb is 3:1.5:1) and alcohol extracts thereof have the function of promoting bile secretion of white rats, but the herba artemisiae scopariae decoction is not obvious enough, and the herba artemisiae scopariae decoction only slightly reduces gallbladder contraction (X-ray examination) of normal people and does not obviously change the volume. The water extract and refined concentrated extract (both with or without volatile oil removed) of herba Artemisiae Scopariae have obvious choleretic effect on acute gallbladder intubated and chronic gallbladder fistula dog, and the active ingredients are presumed to be water and alcohol soluble substances, while the volatile sleeve has suspicious or weaker effect; however, it has also been reported that the volatile oil isolated from oriental wormwood in Nanjing has a choleretic effect on guinea pigs. Pain relieving and anti-inflammatory effects: herba Artemisiae Scopariae has obvious heat clearing effect on rabbit body temperature rise caused by typhoid mixed vaccine, 6, 7-dimethyl esculin in herba Artemisiae Scopariae has certain analgesic effect on mouse pain model caused by hot plate method and acetic acid writhing method, and has inhibitory effect on rat plantar joint swelling degree caused by carrageenan. Treating neonatal jaundice: neonatal jaundice is usually caused by immature hepatocytes and insufficient body compensation function, and can affect the growth and development of the neonate, so it should be treated at an early stage. The herba artemisiae scopariae and Chinese date soup has the effects of promoting the activity of liver cells, tonifying qi, promoting the production of body fluid, protecting the liver and removing jaundice. The method has the advantages of good curative effect, simple usage and no side effect, and is worthy of clinical popularization and application. The function of reducing blood pressure: the herba Artemisiae Scopariae water extract and refined extract have blood pressure lowering effect, and 6, 7-dimethoxy coumarin essence intravenous injection and duodenum administration have blood pressure lowering effect on rat, cat, rabbit, and dog, which is caused by central and visceral vessel dilatation; the coronary flow of the isolated ventricular fibrillation rabbit heart is obviously increased, and the rhythm contraction of the isolated ventricular fibrillation rabbit heart is recovered. Effect on experimental hepatitis: experiments show that the artemisia capillaris decoction, the artemisia capillaris and the gardenia rhubarb decoction can reduce the death rate of carbon tetrachloride toxic hepatitis of mice, the cholagogic effect of the artemisia capillaris water extract and the refined concentrated extract on a flat stone with ropes attached at the sides tetrachloro toxic hepatitis dogs is more obvious than that of normal dogs, the artemisia capillaris decoction and the artemisia capillaris volatile oil have no influence on serum transaminase of carbon tetrachloride toxic hepatitis rabbits, but the latter can increase the food intake of the hepatitis rabbits, and have no effect of improving the death rate and liver cell lesion of the mice with viral hepatitis. The herba Artemisiae Scopariae decoction has effect in promoting liver cell regeneration of rabbit. The diuretic effect is: the water extract, the refined concentrated extract and the 6, 7-dimethoxy coumarin of the oriental wormwood all have diuretic effect on dogs; the herba Artemisiae Scopariae volatile oil can increase urine volume of rabbit with toxic hepatitis, and the urine color changes from yellow to clear. Therefore, the capillary artemisia can have the function of promoting urination. Other functions are as follows: the capillary artemisia decoction can reduce serum cholesterol and beta-lipoprotein after being taken for 2-3 weeks for experimental atheromatous rabbits by 3g/kg, wherein the beta/gamma ratio is lower than that of a control group, but the C/P value is higher than that of the control group. That is, Artemisia capillaris exhibits a protective effect on pathological changes of aortic arch and visceral fat deposition.
Longhairy antenoron herb, original name zanthoxylum micranthum, alias: lysimachia christinae hance, specular grass, aleppo stephania, lotus bud grass, meat wonton grass, gold key, glechoma longituba and the like. The Latin article name is Dichondra depends Forst. Tubular florales, Convolvulaceae, perennial creeping small herbs. The leaf kidney is shaped to be round, the diameter is 4-25 mm, the flower is single-grown, the axilla is axillary, the flower stalk is shorter than the leaf stalk, and the flower stalk is filiform; green leaves, yellow florets. Mainly distributed in tropical and subtropical regions of the two hemispheres. The whole herb is used for medicine, and has the functions of clearing heat and promoting diuresis, dispelling wind and relieving pain, stopping bleeding and promoting granulation, diminishing inflammation and detoxifying, and killing insects. Can be used for treating acute and chronic hepatitis, icteric hepatitis, cholecystitis, nephritis, urinary system infection, tonsillitis, stomatitis, carbuncle, furuncle, toxic substance, acute mastitis, dysentery, malaria, and pulmonary hemorrhage. Lysimachia christinae Hance is sweet, slightly bitter and cool in nature. It enters liver, gallbladder, kidney and bladder meridians. The lysimachia christinae hance is a common plant and a traditional Chinese medicine, has the main effects of preventing calculi, benefiting gallbladder and removing calculi, has very good treatment and prevention effects on calculi, and promotes diuresis for treating stranguria; clearing away heat and toxic materials; removing blood stasis and swelling, clearing away dampness and heat, treating stranguria with sand, pain in urination, jaundice, dark urine, carbuncle, furuncle, and treating calculus of liver, gallbladder and urinary system; hot spraying; edema due to nephritis; jaundice due to damp-heat; sores, abscess and swelling; bite by poisonous snake; traumatic injury. The whole herba Lysimachiae Christinae is used for medicine, and has effects of clearing heat, promoting diuresis, dispelling pathogenic wind, relieving pain, stopping bleeding, promoting granulation, diminishing inflammation, removing toxic substance, and killing parasite. Can be used for treating acute and chronic hepatitis, icteric hepatitis, cholecystitis, nephritis, urinary system infection, tonsillitis, stomatitis, carbuncle, furuncle, toxic substance, acute mastitis, dysentery, malaria, and pulmonary hemorrhage. The stone removing effect: the herba Lysimachiae Christinae has effects of promoting gallbladder function and removing urinary calculus. The polysaccharide component in the alcohol insoluble substance of herba Lysimachiae Christinae has effect in inhibiting crystallization of calcium monohydrochloride CaCO HO as main component of lithangiuria. And the inhibitory effect increases with increasing concentration. Lysimachia christinae Hance can also make blood and urine acidic, and dissolve calculus which can only exist in alkaline environment. Slowing the growth rate of CaCO HO and reducing the degree of crystal aggregation, thereby being beneficial to treating calculus. Is widely applied in modern clinic and achieves good effect. The common people usually drink the tea drink because the longhairy antenoron herb can be used for clearing heat, promoting urination and removing urinary calculus. The function of gallbladder promotion: pharmacological and clinical tests prove that the traditional Chinese medicine preparation has the choleretic effect, and the choleretic effect can be used for promoting liver cells to secrete bile, so that the juice in the inner container of the liver and gallbladder is increased, the internal pressure is increased, and the sphincter Oddi is relaxed, so that the bile excretion is increased. Thrombus inhibition: the herba Lysimachiae Christinae total flavonoids can remarkably reduce wet weight and dry weight of venous thrombosis in rat body under pathological state, reduce percentage of thrombosis, and show remarkable thrombosis inhibiting effect. Enhancing the immunity: the herba Lysimachiae Christinae has effect in inhibiting cellular immunity and enhancing phagocytic function of mouse macrophage. Lysimachia christinae Hance is useful as an immunosuppressant for organ transplantation or autoimmune diseases.
Red sage root, also known as: cleft cicada grass (Benjing), Benma grass (Tetranychus Bengal), and Salvia longata. Perennial herbs with a height of 30-80 cm are densely covered by yellow-white soft hair and glandular hair. Slender cylindrical root, vermilion skin. The old roots are loose in outer skin, often purple-brown and often flaky. Hard and brittle, loose cross section, fissured or slightly flat and compact, reddish brown skin, grayish yellow or purple brown wood, yellow-white canals, radially arranged. Light smell, slightly bitter and astringent taste. The stem is upright and square, and the surface is provided with a shallow groove. The flowering period is 5-8 months. The fruit period is 8-9 months. Mainly produced in Anhui province, Shanxi province, Hebei province, Sichuan province, Jiangsu province, etc. In addition, Hubei, Gansu, Liaoning, Shaanxi, Shandong, Zhejiang, Henan, Jiangxi, etc. The red sage root is a perennial herb, is 30-100 cm high, and is densely covered with faint yellow vellus and glandular hair of the whole plant. Slender root, cylindrical shape and earthy red skin. The stem is quadrangular, and the upper part is branched. Leaf pair, single feathered complex leaf, small oval to wide oval, dense white and soft hair on both sides. In summer, 3-10 flowers are arranged in each round of the cymbidium floribundum floribunda and the cymbidium floribundum and the cymbidium floribundum are bloomed at the top and in the axillary, and are arranged in a plurality of rounds to form a detached general inflo; the calyx is slightly bell-shaped and purple; 2 corolla in blue-purple color, 2 developing stamens extending out of the corolla tube to cover under the upper lip, and 2 degenerated stamens growing on two sides of the throat of the upper lip; the ovary is superior, 4 deep cracks, the style is longer than the stamen, and the 2 splinters of the stigma are unequal. The small nuts are oblong, dark brown or black when cooked, and are wrapped in the persistent calyx. The root and stem of red sage root are short, thick, long and thin, and slightly curved, and have a length of 10-25 cm and a diameter of 0.5-1.5 cm. The surface is brownish red or brick red, rough and has irregular longitudinal wrinkles; the outer skin is exfoliated in scaly pieces. Firm and crisp. The section is loose; dark reddish-brown bark, grayish-yellow or purple-brown xylem; the vascular bundles are yellowish white and radially arranged. The thick strips and purple red are preferred. The flowering period is 5-7 months, and the fruit period is 8 months. The red sage root has synergistic effect on the anticancer activity of camptothecin and cyclophosphamide, the red sage root has cytotoxic effect on sarcoma 180 cells, the przewaquinone A which is an obvious antitumor active component separated from the red sage root has different degrees of inhibition effect on mouse Lewis lung cancer, melanoma 1316 and sarcoma 180, the red sage root has two different reports on the tumor effect: the experiment shows that the salvia miltiorrhiza has the function of promoting cancer metastasis, and the application of the salvia miltiorrhiza alone has obvious promotion function on the spontaneous lung metastasis of Lewis lung cancer mice; the compound red sage root injection (containing red sage root and dalbergia wood) is applied alone to promote the blood diffusion of rat Walker256 cancer cells. The red sage root injection can reduce cholesterol of partial patients, the red sage root decoction taken orally has no function of reducing blood fat and no protection effect on aortic lesion in experimental atherosclerosis rats, but can reduce triglyceride in blood and liver for atherosclerosis rabbits. The red sage root has the function of promoting wound healing, and can relieve local blood stasis, improve local circulation and promote fracture healing for the rabbits with artificial fractures. It has effects in promoting fracture healing, and can be used for improving serum zinc content, enhancing zinc mobilization in bone tissue adjacent to fracture end, and accelerating callus tissue growth and calcification process by increasing zinc content and zinc/copper ratio in callus. In addition, the salvia miltiorrhiza decoction is injected into rabbits for reducing blood sugar. Tanshinone has mild estrogen-like activity and has anti-androgen effect. The Saviae Miltiorrhizae radix preparation can inhibit collagen synthesis and promote decomposition of connective tissue pathological changes, and can be used for treating scleroderma and cicatricial diseases. The salvia miltiorrhiza decoction is injected into the abdominal cavity of a mouse by 43g/kg, no animal death is seen in the abdominal cavity injection for 48 hours and l times, and 2 animals die in 10 animals in a 64g/kg group. The ethanol soluble part of the salvia miltiorrhiza is 80.5 +/-3.1 g of crude drug/kg of the mouse subjected to intraperitoneal injection for 1 time, and the half lethal dose of the salvia miltiorrhiza or compound salvia miltiorrhiza injection is 136.7 +/-3.8 g/kg and 61.5 +/-5.3 g/1g of mouse subjected to intraperitoneal injection respectively. (in terms of crude drug content); the injection is 2.4g/kg per day or 3g/kg per day for 14 days, and has no toxic reaction, no abnormal changes in hemogram, liver and kidney function and body weight, and no special change in parenchymal organs except obvious hyperemia. In addition, the mice were gavage daily for 14 days with 0.5ml of the tanshinone suspension solution 2% and the rats were gavage daily for 10 days with no toxicity. Intraperitoneal injection of a half lethal dose in mice: 36.7 plus or minus 3.8g/kg of salvia miltiorrhiza injection and 61.5 plus or minus 5.26g/kg of compound salvia miltiorrhiza injection. The two preparations are injected into the anaesthetized animals intravenously, the clinical application amount is 40-80 times, and no toxic reaction is caused; the rabbit is intravenously injected with 20-30 times of clinical dosage every day for 14 consecutive days, no toxic reaction is observed, no adverse effect is caused to hemogram, liver and kidney functions and weight, and parenchymal organs show special changes except obvious hyperemia.
Cyperus rotundus, named Cyperus rotundus, was recorded in the miscellaneous records of famous physicians, listed as a Chinese food. Cyperus rotundus is named as the book Tang Ben Cao (herbal Tang materia Medica). The compendium of materia medica lists the herbs in the ministry of herbage, named "cyperus rotundus", and yunyun: the method comprises the steps of cutting a common burreed rhizome into hollow parts in five or six months, repeating a plurality of leaves at the stem end, cutting a blue and white flower into a panicle like millet, cutting a fine seed in the middle, cutting a beard at the root, setting one or two seeds below, rotating and growing the seeds in a phase-extending way, cutting two tips of the large one like sheep jujube, burning and removing the hair, and drying the product quickly. The nutgrass galingale rhizome has the following properties: pungent, slightly bitter and sweet with mild taste. The nutgrass galingale rhizome enters meridians: enter lung, liver, spleen and stomach meridians. The function of the rhizoma cyperi is as follows: regulating qi-flowing, resolving stagnation, regulating menstruation and relieving pain. The nutgrass galingale rhizome is mainly used for treating: can be used for treating stagnation of qi due to depression of the liver, distending pain of chest, hypochondrium, and abdomen, dyspepsia, menoxenia, amenorrhea, dysmenorrhea, cold hernia, abdominal pain, and breast pain. The nutgrass galingale rhizome has the following main functional indications: regulating qi and resolving stagnation; regulating menstruation and relieving pain; preventing miscarriage. Distending pain in the hypochondrium; breast distending; hernia pain; menoxenia; epigastric and abdominal fullness and pain; belching, acid regurgitation, nausea and vomiting; abdominal pain during menstruation; metrorrhagia and metrostaxis and leukorrhagia; threatened abortion. Can be used for treating stagnation of qi due to stagnation of liver-qi, chest pain, hypochondrium pain, abdominal distention and pain, dyspepsia, chest and abdominal distention and fullness, hernia due to cold, abdominal pain, breast pain, menoxenia, amenorrhea, and dysmenorrhea. The efficacy of the nutgrass galingale rhizome is as follows: to soothe the liver, relieve depression, regulate qi, relieve epigastric distention, regulate menstruation and alleviate pain. The pharmacological actions of cyperus rotundus are reported as follows: synergistic effect on subthreshold dose pentobarbital: the report of the Cynanchum Liu et al shows that mice are respectively injected with different dosages of nutgrass galingale rhizome volatile oil 0.03, 0.06 and 0.10ml/kg (1/10, 1/5 and 1/3 median lethal dose respectively) in the abdominal cavity, 30 minutes after administration, the mice in each group are injected with subthreshold dosages of pentobarbital sodium 20mg/kg in the abdominal cavity, and the number of sleeping mice in each group is observed by taking the disappearance of righting reflex as a sleeping index. The results show that the cyperus rotundus volatile oil with different dosages can be obviously cooperated with the hypnotic effect of the pentobarbital sodium on mice (P is less than 0.01). Anesthetic action on normal rabbits: slowly and intravenously injecting rhizoma Cyperi volatile oil 0.050, 0.075 and 0.100mg/kg into rabbit, and average anesthesia time is 9.0, 15.0 and 28.5 minutes. After the animals in each group are dosed, the turning-over positive reflex disappears rapidly, and in the group with the dose of 0.050mg/kg, the rabbit pain reaction and corneal reflex are slow, and the auditory reaction exists; the pain response and corneal reflex of the rabbits of the other two dose groups completely disappeared, and the auditory response existed. After administration, the rabbits of each group had a strong and straight limb phenomenon, and disappeared after about 3 minutes. Synergistic scopolamine anesthetic action: the disappearance of the righting reflex is used as an index of anesthesia, and the average anesthesia time of each group of rabbits is observed. The first group of volatile oil of rhizoma Cyperi for intravenous injection is 0.075ml/kg, and has the appearance of turning over the normal reflection and disappearance. The second group was injected intracerebroventricularly with scopolamine. The third group has the advantages that the injection of the volatile oil of nutgrass galingale rhizome by intravenous injection of 0.035ml/kg (no disappearance of righting reflex) and the subsequent intracerebroventricular injection of scopolamine of 2mg/kg show that the dosage of 0.035ml/kg has no anesthetic effect, and can obviously prolong the anesthetic time of the scopolamine without influencing the anesthetic depth. Effect on pentylenetetrazol convulsions: the mice are injected with 0.1ml/kg (1/3 half lethal dose) of nutgrass galingale rhizome volatile oil in the abdominal cavity, 30 minutes after the administration, the ih pentylenetetrazol is 85mg/kg, and the clonic convulsion number of the mice is observed. The result shows that the nutgrass galingale rhizome volatile oil has no protective effect on mouse convulsion caused by the pentylenetetrazol. SinghN et al also reported that the alcohol extract of Cyperus rotundus L had no protective effect on mouse pentaerythrine and electric shock. Antipyretic analgesic effect: the dansu glossy privet et al reports that the injection of 20% nutgrass galingale rhizome alcohol extract into mice subcutaneously can obviously improve the pain threshold of the mice. The pain threshold of the Liu Guoqin and the like is determined by a hot plate method, 0.1ml/kg of nutgrass galingale rhizome volatile oil is injected into the abdominal cavity of a mouse, 10mg/kg of salt morphine is injected into the abdominal cavity as a control, and the pain threshold of each mouse is determined 15 minutes, 30 minutes, 60 minutes and 90 minutes after administration. The result shows that the nutgrass galingale rhizome volatile oil has no obvious analgesic effect. GuptaMB reports that the analgesic effect of 5mg/kg of triterpenoid (IV-B) contained in the cyperus rotundus alcohol extract after being infused is equivalent to 30mg/kg of acetylsalicylic acid. The rhizoma Cyperi alcohol extract has antipyretic effect on rat fever caused by yeast injection, its potency is about 6 times of sodium salicylate, and its antipyretic effective component is also triterpenes. Cooling: injecting rhizoma Cyperi volatile oil 0.1ml/kg into abdominal cavity of rat, injecting chlorpromazine 5mg/kg into abdominal cavity as positive control, and measuring rectal temperature of rat before and after administration. The result shows that the normal body temperature (P is less than 0.05) of a rat can be obviously reduced after the cyperus rotundus volatile oil is administered for 30 minutes, the temperature reduction effect is stronger than that of chlorpromazine, but the effect is less than that of chlorpromazine for a long time, and then the body temperature of the rat is gradually restored to normal. : akperbekova, ba, et al, reported that the frog heart can be stopped in the systolic phase by injecting a water or hydroalcoholic extract of a spice under the frog skin. At lower concentrations, the composition can be used for tonifying heart or slowing down heart rate in vitro, in vitro frog heart, in vivo frog heart, rabbit heart and cat heart. The water solution of rhizoma Cyperi total alkaloids, glycosides, flavonoids and phenolic compounds also has effects of tonifying heart and slowing heart rate, and has obvious effect of lowering blood pressure. The influence of volatile oil of rhizoma cyperi on the blood pressure of cats is researched by the radix cynanchi paniculatae and the like. Cats were anesthetized with aldochlorose sugar 80mg/kg and were recorded for carotid blood pressure. After 0.1ml/kg of nutgrass galingale rhizome volatile oil is intravenously injected to an anaesthetized cat, the blood pressure of the cat begins to decrease 15 seconds later, the blood pressure is reduced by 10.7-13.3kPa after 150 seconds compared with the normal blood pressure, the blood pressure begins to rise after 5 minutes, and the blood pressure basically recovers to the normal level after 8 minutes. Transient blood pressure drops are thought to be associated with their local effects. SinghN et al, administered intravenously to anesthetized dogs at 20mg/kg with ethanol extract of Cyperus rotundus L, slowly lowered blood pressure for 0.5-l hr. The ethanol extract does not affect the effect of adrenalin and acetylcholine on blood pressure, but partially blocks the effect of histamine. IndraM et al report that the ovariectomized rat experiment shows that the volatile oil of nutgrass galingale rhizome has slight estrogen-like activity. 0.2ml of volatile oil is injected subcutaneously for 2 times at intervals of 6h, and the vaginal epithelium is completely keratinized after 48 hours; when 0.3ml was administered three times, many leukocytes appeared in a large number of keratinocytes. The appearance of leukocytes may be due to the irritating effects of the essential oils. The Cyperene (Cyperene) I has the strongest effect in the components separated from the volatile oil, but is not as much as the volatile oil per se. When administered intravaginally, the volatile oil, cyperene I and cyperone can cause epithelial keratinization, while cyperol and cyperene II have no effect. The effective dose of the effective component for systemic administration is not more than one time of the local dosage. It is therefore believed that these components may belong to the class of proestrogens (ProescTCMLIBagen) which have enhanced activity following transformation in vivo. The action of cyperus rotundus is one of the main bases for treating irregular menstruation. Zhang Fang et al report that 5% rhizoma Cyperi fluid extract has inhibitory effect on isolated uterus of animals such as guinea pig, rabbit, cat and dog, no matter pregnant or not pregnant, so that its contractility is weakened and muscle tension is reduced. Its action properties are quite similar to angelicin, but weaker. SinghN reports that 100mg/kg of cyperus alcohol extract is injected into the abdominal cavity, and has obvious inhibition effect on the rat foot swelling caused by carrageenan and formaldehyde. The effect is stronger than that of 5-10mg/kg of hydrocortisone. GuptaMB studies have demonstrated that its anti-inflammatory component is a triterpenoid. Wherein the component IV-B has anti-inflammatory effect on foot swelling caused by carrageenan, and has a safety range 3 times larger than that of hydrocortisone by 8 times. It also has inhibiting effect on formaldehyde-induced foot swelling. The ratio of the effectiveness of the gavage and the intraperitoneal injection is 1: 3, indicating that it may be only partially absorbed in the digestive tract. The report of the Cynanchum Liuhuanense et al, rabbit isolated intestinal canal is prepared by the conventional method, and the influence of Cyperus rotundus volatile oil on the isolated intestinal canal is recorded by using tamarind. The result shows that when the concentration of the volatile oil of the nutgrass galingale rhizome is 5 mu g/ml, the contraction of the intestinal canal can be inhibited, and when the concentration is increased to 20 mu g/ml, the obvious inhibition effect is achieved, so that the contraction amplitude of the intestinal canal is reduced, and the tension is reduced. SinghN also reports that the cyperus rotundus alcohol extract has direct inhibition effect on isolated rabbit ilex smooth muscle at the concentration of 20 mu g/ml. In vitro tests show that the volatile oil of rhizoma cyperi has an inhibitory effect on staphylococcus aureus and is ineffective on other bacteria. The cyperene I and II have stronger bacteriostatic action than the volatile oil and are also effective on dysentery bacterium sonnei. Hydrogenation does not affect its antimicrobial action. Cyperone is completely ineffective. The Cyperus rotundus extract also has inhibitory effect on certain fungi. : the rhizoma Cyperi alcohol extract has protective effect on guinea pig bronchial spasm due to histamine spray. The prostaglandin biosynthesis inhibiting substance contained in rhizoma Cyperi is mainly a-Cyperone (a-Cyperone).
Bupleuri radix, Chinese medicine for clearing deficiency heat, and can be used for treating common cold, fever, alternating chills and fever, malaria, stagnation of qi due to depression of the liver, distending pain of chest and hypochondrium, rectocele, metrorrhagia, and menoxenia. Chai Hu is listed as the superior product in Shen nong Ben Cao Jing (Shen nong's herbal). The herb of the past generation has been described about the plant morphology of Bupleurum. The book draft classic: the former is in the close region of Guang, shan and Jiang lake, and the former is superior to Yinzhou. February sprout, very fragrant, green purple stem, leaf like bamboo leaf purple … … Qiyue yellow flower … … red, strong like Peucedanum praeruptorum. Red hair like rat tail is found in reed heads, while Du nest is good. Collecting roots in February August. Wherein the picture of Danzhou radix bupleuri, Xiangzhou radix bupleuri, Zizhou radix bupleuri, and Zhuyehu radix bupleuri in Ben Cao gang mu, and the picture of Bupleurum chinense in Jie Yao Ben Cao are all plants of Bupleurum. Property, flavor and meridian tropism of bupleurum: slightly cold in nature, bitter and pungent in flavor, entering liver and gallbladder meridians, and has the effects of soothing liver, promoting bile flow, dispelling qi, resolving stagnation and dissipating fire. The bupleurum has the main functions: expelling pathogenic factors from the exterior, clearing away heat, dispersing stagnated liver qi, and invigorating yang; the main treatment is as follows: liver qi stagnation, distending pain in chest and hypochondrium, rectocele, uterus drop, and irregular menstruation. Bupleuri radix can be used for treating common cold, fever, alternating chills and fever, distending pain in chest and hypochondrium, menoxenia, uterine prolapse, and proctoptosis. The bupleurum has the following pharmacological functions: and (3) clearing heat: the effective components are as follows: volatile oil (eugenol, caproic acid, gamma-undecanoic acid lactone and p-methoxybenzenedione), and saikosaponin (sapogenin A). The function is as follows: has obvious heat-clearing effect on fever caused by typhoid, paratyphoid vaccine, colibacillus liquid, fermented milk, yeast and the like; and can lower the normal body temperature of the animal. The commercial bupleurum decoction of 2g/kg is used for feeding the stomach of rabbits, and has obvious antipyretic effect on fever caused by vaccine and warm stings. Anti-inflammatory: the effective components are as follows: a saponin is provided. The function is as follows: can be used for inhibiting ankle swelling and connective tissue proliferative inflammation caused by various inflammation agents. 300mg/k of saikosaponin is injected into abdominal cavity to inhibit rat plantar swelling caused by carrageenan, 5-hydroxytryptamine and histamine, inhibit rat cotton ball granuloma, and simultaneously make adrenal gland hypertrophy and thymus gland atrophy; inhibit histamine release and leukocyte migration in inflammatory tissue. And (3) promoting the immune function: the effective components are as follows: and (3) bupleurum polysaccharide. The function is as follows: enhancing phagocytic function, enhancing natural killer cell function, increasing virus specific antibody titer, increasing lymphocyte nuclear transfer rate, and improving skin delayed anaphylaxis. Anti-liver injury: 1ml of bupleurum injection (concentration is 1: 1) per subcutaneous injection for 5 consecutive days can obviously reduce the increase of rat serum GPT caused by carbon tetrachloride, obviously reduce the degeneration and necrosis of liver cells, and lead and ribonucleic acid content in the liver cells to be close to normal. Radiation damage resistance: the survival rate of irradiated mice can be improved by intraperitoneal injection of 5 mg/mouse of bupleurum polysaccharide, the incorporation of 3H-TdR in thymocytes of mice is increased, the release of thymocytes is accelerated, and the plasma is skinned. The increase in the content of corticosterone, which is no longer apparent after removal of the adrenal gland, is thought to be achieved through the adrenal cortex. In addition, it has anti-tubercle bacillus effect in vitro. Pharmacological action research progress: is connected with a traditional Chinese medicine pharmacological research database.
The dark plum is named as dark plum, yellow boy, Hehan plum and dry branch plum, and is prepared by smoking nearly mature fruit of plum Prunus mumme which is a deciduous tree plant of Rosaceae. If the plum is soaked in saline water in the sun and the night, white frost is formed after 10 days, so the plum is called as white frost plum, and the efficacies are similar and the same should not be considered. According to modern research, green plum or plum juice. Dark plum contains much potassium and less sodium, so people who need to take potassium-excreting diuretics for a long time should eat the dark plum; since the plum contains catechin, it is suitable for people with constipation because it can promote the intestinal motility. The plum contains various organic acids, and has the effect of improving liver function, so it is suitable for patients with liver diseases. The pruric acid in mume fructus has effects of softening blood vessel, delaying angiosclerosis, and resisting aging. The meridian tropism of dark plum: it enters liver, spleen, lung and large intestine meridians. The dark plum has the following effects: astringe lung, astringe intestine, promote fluid production and relieve ascaris. The function of the dark plum is mainly indicated: can be used for treating lung deficiency, chronic cough, chronic diarrhea, dysentery, asthenia heat, diabetes, ascariasis, emesis, and abdominal pain.
Cassia seed, synonym: cassia occidentalis, ram (Wu Pu Ben Cao), cavel (Guang ya), water chestnut (pottery hong Jing), fructus pupillae (medical science Zheng Chuan), herba crinis Canitis (raw herb medicine preparation), pseudo-mung bean (Chinese medicine record), water chestnut (Jiangsu medicine record), groundsel (Shanxi Chinese medicine record)), celery (Shanxi Chinese medicine record), sheep's horn bean (Guangdong Chinese medicine record), wild green bean (Jiangxi herbal medicine record), pig bone Ming, pig's faecia Sus Domestica, thin leaf pig's faecia, night La Zi, and sheep tail bean (southern toxic plant). The semen cassiae has the following properties: bitter and slightly cold. Cassia seed has the functions of clearing away heat, improving eyesight, moistening intestine and relaxing bowels. Can be used for treating conjunctival congestion, photophobia, lacrimation, headache, vertigo, dim eyesight, and constipation. Cassia seed, semen Cassiae, enters liver, kidney and large intestine meridians. Has the effect of reducing weight. It can be used for treating wind-heat type acute contagious conjunctivitis, cyanosis, bromhidrosis, hypertension, hepatitis, ascites due to liver cirrhosis, and habitual constipation. The cassia seed has the following pharmacological actions. The antibacterial effect is as follows: the semen Cassiae alcohol extract has inhibitory effect on Staphylococcus, diphtheria bacillus, typhoid fever, paratyphoid fever, and Escherichia coli, while the water extract is ineffective. Antifungal action: the cassia seed water infusion (1: 4) has different degrees of inhibition effects on dermatophytes such as trichophyton gypseum, yellow ringworm of the orchid, and the ozocerite ringworm of the Odong. The semen Cassiae contains chrysophanol-9-anthrone, and has strong inhibitory effect on Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum, and Geotrichum. The function of reducing blood pressure: the cassia seed water extract, alcohol-water extract and alcohol extract have the function of reducing blood pressure for anesthetizing dogs, cats, rabbits and the like. In chronic experiments, the decoction is 2g (crude drug)/kg per day, and has no effect of lowering blood pressure. The intravenous injection of 0.05g/100g weight of the cassia seed injection can obviously reduce the systolic pressure of spontaneous hereditary hypertension rats and simultaneously obviously reduce the diastolic pressure, and the blood pressure reducing effect, the blood pressure reducing amplitude and the action time of the cassia seed injection are all superior to those of rats in the group of intravenous injection reserpine of 0.3 mg/kg. Effects on hyperlipidemia: when the high-fat beverage containing 7 percent of cassia seed is fed to mice for 2 weeks, the cassia seed can not influence the Total Cholesterol (TC) level of serum, but can obviously increase the content of high-density lipoprotein-cholesterol (HDL-C) of the serum and improve the ratio of HDL-C/TC, namely, the distribution condition of the cholesterol in the body is obviously improved, and the high-fat beverage is favorable for preventing atherosclerosis. Anti-platelet aggregation effect: cassia tora has the effect of resisting platelet aggregation induced by Adenosine Diphosphate (ADP), Arachidonic Acid (AA) and collagen (collagen). 3 anthraquinone compounds in cassia seed, such as aurantio-obtusin, semen cassiae element and emodin, have weak activity of resisting platelet aggregation. From the results, 3 anthraquinone glycoside compounds, namely glucosyl-mayonnaise, glucosyl-aurantio-obtusin and glucosyl-luteinin, are found to have strong platelet aggregation inhibition effects. Impact on immune function: the cassia seed water decoction alcohol precipitation agent is injected subcutaneously with 15g/kg, so that the thymus of a mouse is atrophied, the ANAE (ANAE staining negative rate of peripheral blood lymphocytes) is obviously reduced, the delayed type hypersensitivity reaction of the skin of the mouse caused by 2, 4-Dinitrochlorobenzene (DNCB) is inhibited, but the formation of serum hemolysin is not obviously influenced, in addition, the cassia seed water decoction alcohol precipitation agent can obviously increase the percentage of chicken red blood cells phagocytosed by macrophages in the abdominal cavity of the mouse and the phagocytosis index, and the lysozyme level is also obviously higher than that of a control group. Liver protection: 670mg/kg hot water extract of semen Cassiae has weak detoxifying effect on mouse liver with carbon tetrachloride poisoning. The cassia seed is degreased by petroleum ether, extracted by chloroform and then extracted by methanol, and the methanol extract has obvious liver protection effect. Further, chrysophanol-l-O-tri-glucoside and chrysophanol-1-O-tetra-glucoside obtained from the raw materials have weak protective effect on liver cells damaged by carbon tetrachloride at 1mg/ml, and aloe-emodin also has similar anti-hepatotoxicity effect. Purgative effect: semen Cassiae has laxative effect. The fluid extract reaches the peak after the purgation after being taken orally in 3-5 h. Obtaining 50% ethanol soluble part from the water decoction, sequentially adding ethyl acetate and butyric acid to obtain soluble part and water soluble part respectively. Separating butanol fraction with highest purgative activity with Sephadex column to obtain several fractions, and hydrolyzing the fractions with activity with acid to obtain chrysophanol, dianthrone and d-glucose. After oral administration of these components, the condensation product of nitrosodiphenylamine and chrysophanol anthrone were detected in the large intestine, but the purgative activity was halved and the anthrone formation was reduced in mice treated with chloramphenicol to inhibit the proliferation of intestinal bacteria. Effects on gastric secretion: for dogs with gastric fistula, fluid extract of semen Cassiae can promote gastric secretion. Inhibition of 15-hydroxyprostaglandins: the enzyme dehydrogenase (15-OH PGDH) converts prostaglandin E2 having diuretic action into 15-ketoprostaglandin through the action of 15-hydroxyprostaglandin dehydrogenase and excretes it to the outside of the body, and the diuretic action is prolonged by inhibiting the reaction in the body. The semen Cassiae water extract has effect in inhibiting 15-OH PGDH activity. The substances inhibiting the enzyme activity were sequentially extracted with ethane, chloroform, methanol and water, and then separated by column chromatography, and it was found that IC50 of anthraquinone derivatives cassia tora and cassia tora are 1.064 × 10mol/L and 1.666 × 10mol/L, respectively, IC50 of anthraquinone derivatives chrysophanol and physcion are 1.789 × 10mol/L and 1.236 × 10mol/L, respectively, and the inhibitory activities were all weak. The extract of cassia seed is locally injected into the ligated stomach and duodenum of rat in stages, and the remaining amount of extract B is 66% (duodenum) to 88% (colon) of the administered amount by high pressure liquid phase detection, and the amount of the administered amount can be detected by colorimetry, and the detected amount exceeds the administered amount at the lower part of gastrointestinal tract. At these sites, the metabolites formed cannot be detected by high pressure liquid phase, and there is only little absorption of extract B and its known metabolites. After the cassia seed extract iv is administered, the administered amount is 100% unchanged by colorimetry, which indicates that the cassia seed extract is not absorbed or metabolized at various parts of the gastrointestinal tract.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible. The following examples further illustrate the invention without limiting it.
Preparation example 1: preparation of Jinqian Dantong granules
Formula (1000 g of Qianliantong granules are prepared): 750g of longhairy antenoron herb, 375g of giant knotweed rhizome, 375g of dandelion, 562.5g of oriental wormwood, 562.5g of longhairy antenoron herb, 187.5g of salvia miltiorrhiza, 187.5g of prepared nutgrass galingale rhizome, 187.5g of Chinese thorowax root, 187.5g of dark plum fruit, 187.5g of cassia seed, 1g of steviosin and a proper amount of dextrin, so that the final particle weight is 1000 g.
The preparation method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae with 9 times of water for 2 hr, and filtering; adding 7 times of water into the filter residue, decocting and extracting for 1.5 hours, and filtering; mixing the two filtrates for later use;
(3) decocting the rest eight medicinal materials with 9 times of water for 2 hr, and filtering; adding 7 times of water into the filter residue, decocting and extracting for 1.5 hours, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
Preparation example 2: preparation of Jinqian Dantong granules
Formula (1000 g of Qianliantong granules are prepared): 700g of longhairy antenoron herb, 400g of giant knotweed rhizome, 350g of dandelion, 500g of oriental wormwood, 600g of longhairy antenoron herb, 150g of salvia miltiorrhiza, 200g of prepared nutgrass galingale rhizome, 150g of Chinese thorowax root, 200g of dark plum fruit, 150g of cassia seed, 0.5g of steviosin and a proper amount of dextrin so that the final particle weight is 1000 g.
The preparation method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae with 10 times of water for 1 hr, and filtering; adding 6 times of water into the filter residue, decocting and extracting for 2 hours, and filtering; mixing the two filtrates for later use;
(3) decocting the rest eight medicinal materials with 8 times of water for 3 hr, and filtering; adding 8 times of water into the filter residue, decocting and extracting for 1 hour, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
Preparation example 3: preparation of Jinqian Dantong granules
Formula (1000 g of Qianliantong granules are prepared): 800g of longhairy antenoron herb, 350g of giant knotweed rhizome, 400g of dandelion, 600g of oriental wormwood, 500g of desmodium, 200g of salvia miltiorrhiza, 150g of prepared rhizoma cyperi, 200g of radix bupleuri, 150g of dark plum, 200g of cassia seed, 1g of steviosin and a proper amount of dextrin so that the final particle weight is 1000 g.
The preparation method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae with 8 times of water for 3 hr, and filtering; adding 8 times of water into the filter residue, decocting and extracting for 1 hour, and filtering; mixing the two filtrates for later use;
(3) decocting the rest eight medicinal materials with 10 times of water for 1 hr, and filtering; adding 6 times of water into the filter residue, decocting and extracting for 2 hours, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
Preparation example 4: preparation of Jinqian Dantong granules
Formula (1000 g of Qianliantong granules are prepared): 500g of longhairy antenoron herb, 450g of giant knotweed rhizome, 300g of dandelion, 700g of oriental wormwood, 450g of desmodium, 250g of salvia miltiorrhiza, 100g of prepared nutgrass galingale rhizome, 250g of Chinese thorowax root, 100g of dark plum fruit, 250g of cassia seed, 1g of steviosin and a proper amount of dextrin, wherein the weight of the final particles is 1000 g.
The preparation method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae with 10 times of water for 1 hr, and filtering; adding 6 times of water into the filter residue, decocting and extracting for 2 hours, and filtering; mixing the two filtrates for later use;
(3) decocting the rest eight medicinal materials with 8 times of water for 3 hr, and filtering; adding 8 times of water into the filter residue, decocting and extracting for 1 hour, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
Preparation example 5: preparation of Jinqian Dantong granules
Formula (1000 g of Qianliantong granules are prepared): 1000g of longhairy antenoron herb, 300g of giant knotweed rhizome, 450g of dandelion, 450g of oriental wormwood, 700g of longhairy antenoron herb, 100g of salvia miltiorrhiza, 250g of prepared nutgrass galingale rhizome, 100g of Chinese thorowax root, 250g of dark plum fruit, 100g of cassia seed, 0.5g of steviosin and a proper amount of dextrin, wherein the weight of the final particle is 1000 g.
The preparation method comprises the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae with 8 times of water for 3 hr, and filtering; adding 8 times of water into the filter residue, decocting and extracting for 1 hour, and filtering; mixing the two filtrates for later use;
(3) decocting the rest eight medicinal materials with 10 times of water for 1 hr, and filtering; adding 6 times of water into the filter residue, decocting and extracting for 2 hours, and filtering; mixing the two filtrates for later use;
(4) and (3) mixing the filtrates obtained in the step (2) and the step (3), concentrating under reduced pressure to obtain clear paste with the relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of auxiliary materials, mixing uniformly, granulating and drying to obtain the traditional Chinese medicine composition.
Preparation example 6: preparation of money Dantong granules (Standard)
Formula (1000 g of Qianliantong granules are prepared): 750g of longhairy antenoron herb, 375g of giant knotweed rhizome, 375g of dandelion, 562.5g of oriental wormwood, 562.5g of longhairy antenoron herb, 187.5g of salvia miltiorrhiza, 187.5g of prepared nutgrass galingale rhizome, 187.5g of Chinese thorowax root, 187.5g of dark plum fruit, 187.5g of cassia seed, 1g of steviosin and a proper amount of dextrin, so that the final particle weight is 1000 g.
The preparation method comprises the following steps: respectively cutting the ten medicinal materials into middle blocks, adding 8 times of water, and decocting twice for 1.5 hours each time (wherein 10.5 times of water is added for the first time, and soaking for 1 hour and then decocting); mixing the decoctions, filtering, concentrating the filtrate to obtain a clear paste with a relative density of 1.05-1.10 (55-60 ℃), spray drying to obtain extract powder, adding a proper amount of dextrin and steviosin, mixing uniformly, granulating, and vacuum drying at 60 ℃ to obtain 1000g of the Chinese medicinal preparation.
Preparation example 7: preparation of Jinqian Dantong granules (632# E2)
The formula is as follows: 750g of longhairy antenoron herb, 375g of giant knotweed rhizome, 375g of dandelion, 562.5g of oriental wormwood, 562.5g of longhairy antenoron herb, 187.5g of salvia miltiorrhiza, 187.5g of prepared nutgrass galingale rhizome, 187.5g of Chinese thorowax root, 187.5g of dark plum fruit and 187.5g of cassia seed.
The preparation method comprises the following steps:
1. crushing the desmodium styracifolium into coarse powder, adding 90% ethanol in an amount which is 8 times that of the coarse powder, soaking for 1 hour, refluxing for 3 times and 2 hours each time, combining liquid medicines, filtering, decompressing filtrate, recovering ethanol, and concentrating to obtain clear paste A with the relative density of 1.05-1.10 (55-60 ℃) for later use.
2. The preparation method comprises the following steps of crushing nine medicinal materials of longtube ground ivy herb, giant knotweed rhizome, dandelion, virgate wormwood herb, salvia miltiorrhiza, prepared rhizoma cyperi, radix bupleuri, dark plum fruit and cassia seed into coarse powder, decocting twice for 1.5 hours each time, wherein 12 times of water is added for the first time (soaking for 3 hours and then decocting), 10 times of water is added for the second time, liquid medicines are combined, filtering is carried out, and the filtrate is concentrated to form clear paste B with the relative density of 1.05-1.10 (55-60 ℃) for later use.
3. Mixing the above A, B, spray drying to obtain extract powder, adding 1/3% dextrin and 1.4% sweetener, granulating, vacuum drying at 60 deg.C, grading, and packaging.
Preparation example 8: preparation of JINQIANDANTONG granule (283# E3)
The formula is as follows: 1200g of longhairy antenoron herb, 1500g of longhairy antenoron herb, 600g of giant knotweed rhizome, 800g of oriental wormwood, 800g of dandelion, 300g of Chinese thorowax root, 1000g of salvia miltiorrhiza, 300g of nutgrass galingale rhizome, 200g of dark plum fruit and 200g of cassia seed.
The preparation method comprises the following steps: respectively crushing the ten medicinal materials into middle blocks, adding water for the first time, 69L of water and 55L of water for the second time, decocting twice for 1.5 hours each time, combining the decoction, filtering, concentrating the filtrate to obtain clear paste with the relative density of not less than 1.22 (55-60 ℃), drying the clear paste, crushing into fine powder, adding sucrose powder to 2500g, uniformly stirring, preparing into granules, and packaging with 10g per bag to obtain the product.
Preparation example 9: preparing the jinqianliantong granules: reference is made to the formulations and the preparation of preparations 1 to 5, respectively, except that in step (2) acetic acid is added to the extraction solvent water used, at concentrations of 0.4%, 0.2%, 0.3%, 0.5%, 0.4%, to give 5 batches of granules, which are designated 91#, 92#, 93#, 94#, 95#, respectively. Preparation example 10: preparing the jinqianliantong granules: referring to the formulation and preparation method of preparation examples 1-9, respectively, except that xylitol was added together with dextrin (or sucrose powder) in an amount of 2% by weight of the final granules in the final preparation of granules, 13 batches of granule samples were obtained, which were designated as 101#, 102#, 103#, 104#, 105#, 106#, 107#, 108#, 1091#, 1092#, 1093#, 1094#, 1095 #. Preparation example 11: preparing the jinqianliantong granules: referring to the formulation and preparation of preparation example 10, except that the xylitol added therein was replaced by sorbitol in equal amount, 13 batches of granule samples were obtained, which were respectively designated as 111#, 112#, 113#, 114#, 115#, 116#, 117#, 118#, 1191#, 1192#, 1193#, 1194#, and 1195 #. Preparation example 12: preparing the jinqianliantong granules: referring to the formulation and preparation method of preparation example 10, except that xylitol added therein was replaced with mannitol in equal amount to obtain 13 batches of granule samples, which were respectively designated as 121#, 122#, 123#, 124#, 125#, 126#, 127#, 128#, 1291#, 1292#, 1293#, 1294#, and 1295 #. Preparation example 13: preparing the jinqianliantong granules: since xylitol is also a commonly used filler in pharmacy, this example attempted to use xylitol instead of a filler such as dextrin or sucrose powder used in the formulation; referring to the formulation and preparation method of preparation examples 1-9, respectively, except that dextrin (or sucrose powder) was replaced with xylitol in an amount equal to the amount of the filler in the final preparation of granules, 13 batches of granule samples were obtained, which were designated as 131#, 132#, 133#, 134#, 135#, 136#, 137#, 138#, 1391#, 1392#, 1393#, 1394#, and 1395 #.
Test example 1: detection of typical Components in formulations
The lysimachia used in the granule of desmodium and cholangiolic, for which purpose, for example, CN101380405B (200810166632.X) states that when preparing the granule of desmodium and cholangiolic, the lysimachia is extracted separately in particular, it is very significant to determine the typical chemical components in the preparation that are derived from lysimachia. Typical ingredients of longhairy antenoron herb are quercetin and kaempferide, the sum of which is referred to herein as the indicator.
[ CONTENT DETERMINATION ] is determined by high performance liquid chromatography (2015 edition of the general rules 0512 in the four ministry of Chinese pharmacopoeia).
Chromatographic conditions and system applicability test: octadecylsilane chemically bonded silica is used as a filling agent; methanol-0.4% phosphoric acid solution (50:50) is used as a mobile phase; the detection wavelength was 360 nm. The number of theoretical plates should not be lower than 2500 calculated from the peak of quercetin.
Preparation of control solutions: precisely weighing appropriate amount of quercetin and kaempferide, and adding mobile phase to obtain solutions containing quercetin 4 μ g and kaempferide 20 μ g per 1 ml.
Preparation of a test solution: weighing about 2g of herba Lysimachiae Christinae granules, precisely weighing, placing in a 50ml measuring flask, adding mobile phase for dissolving, and fixing volume, filtering, and collecting the filtrate.
The determination method comprises the following steps: respectively and precisely sucking 20 mu l of reference solution and 20 mu l of test solution respectively, injecting the reference solution and the test solution into a liquid chromatograph, recording a chromatogram, and calculating the total amount of quercetin and kaempferide in the Jinqian Dantong granules, wherein the total amount (mg/g) of quercetin and kaempferide contained in the granules obtained by theoretically feeding 1g of lysimachia christinae hance is used for representing the content of the index substances in the granules. Through measurement, the content of the index of the five batches of granules obtained in the preparation example 9 and the granules obtained in the preparation examples 10 to 13 by the operation method of adding acetic acid into the extraction solvent water according to the preparation method of the preparation example 9 are all within the range of 2.2 to 2.8 mg/g.
Test example 2: stability of the granules
The granules are placed in a sealed bag and placed at 40 ℃ for 5 months, the content of the index substance at 0 month and the content of the index substance at 5 months are measured for each batch of granules, the percentage of the content of the index substance at 5 months relative to the content of the index substance at 0 month is calculated, the percentage is the residual percentage of the index substance after the stability test, the more close the residual percentage is to 100 percent, the more stable the granules are, and generally, if the residual percentage is lower than 90 percent, the insufficient stability of the preparation is indicated. It was found that the residual percentage of the index in the five batches of granules obtained in preparation example 9 and the batches of granules obtained in preparation examples 10 to 13 by the method of adding acetic acid to the extraction solvent water according to the preparation method of preparation example 9 were within the range of 97.3 to 99.5%.
Test example 3: pharmacodynamic test
1. Animals and groups: rats weighing 200-250 gSD, males, weighing, and randomly grouping according to body weight, blank control group (including normal saline group and edible oil control group), and granule group of different preparation examples.
2. And (3) experimental operation: before the experiment, the patient is fasted and not forbidden for 12 hours, before the anesthesia, the patient is perfused with 1ml/100g of normal saline, and then each mouse is anesthetized by intraperitoneal injection with urethane (1g/kg), and is fixed on a fixed plate in the supine position. Cutting about 2cm along the midline of abdomen, opening abdominal cavity, finding stomach pylorus, turning duodenum, and finding white and tough bile duct in mesentery of descending part of duodenum. The bile duct is threaded with 2 silk threads, the papilla is ligated, a V-shaped incision is made towards the liver, a plastic tube is inserted (the faint yellow bile flows out), ligation is performed and fixation is performed, and the bile is collected with a small beaker. The abdominal wall was closed with hemostats after the operation and covered with saline gauze. After 20min of stabilization, 30min of bile is collected, then each group of rats is respectively administrated by duodenum, and a blank control group is administrated with physiological saline or edible oil with equal volume. Collecting bile 1 time every 30min after administration, 3 times in total,
bile flow (ml) was recorded.
3. Results of the experiment
The results are shown in Table 1.
Table 1: bile flow variation before and after administration (x + -S, n ═ 10)
From the above results, it was found that each administration group had a certain bile secretion promoting effect. The difference was very significant or significantly different compared to the blank control group. And granules prepared by using a specific process show obviously more excellent pharmacodynamic results.
The granules for treating the cholangitis comprise ten traditional Chinese medicines of longhairy antenoron herb, virgate wormwood herb, giant knotweed rhizome, Chinese thorowax root, dandelion, nutgrass galingale rhizome (prepared), salvia miltiorrhiza, cassia seed and dark plum fruit, and have the effects of clearing away damp-heat, dredging liver and gallbladder, relieving pain and removing urinary calculus; can be used for treating cholelithiasis with symptoms of hypochondriac pain due to damp-heat stagnation in shaoyang gallbladder, pain in right hypochondrium, immobility, or secondary colic, constipation, yellow urine, fever, dark red tongue, thick and greasy or yellow and greasy tongue coating, and wiry and smooth or wiry and tense pulse.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Claims (5)
1. Every 1000g of the granule is prepared from 700-800 g of Glechomae herba, 350-400 g of giant knotweed rhizome, 350-400 g of dandelion, 500-600 g of oriental wormwood, 500-600 g of desmodium, 150-200 g of salvia miltiorrhiza, 150-200 g of prepared rhizoma cyperi, 150-200 g of radix bupleuri, 150-200 g of dark plum fruit and 150-200 g of cassia seed, and proper auxiliary materials, wherein the auxiliary materials comprise 0.2% of ~ 0.5.5% of steviosin, 1 ~ 5% of xylitol based on the total weight of the granule and a proper amount of dextrin which enables the weight of the final granule to be 1000g, and the granule is prepared by the method comprising the following steps:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae together with 8 ~ 10 times of water for 1 ~ 3 hr, filtering, decocting the residue with 6 ~ 8 times of water for 1 ~ 2 hr, filtering, and mixing the filtrates, wherein the extraction solvent is water containing 0.2 ~ 0.5.5% acetic acid;
(3) decocting the rest eight medicinal materials with 8 ~ 10 times of water for 1 ~ 3 hours, filtering, decocting the residue with 6 ~ 8 times of water for 1 ~ 2 hours, filtering, and mixing the filtrates;
(4) and (3) mixing the filtrates obtained in the steps (2) and (3), concentrating under reduced pressure to obtain fluid extract with a relative density of 1.05 ~ 1.10.10 at 55 ~ 60 ℃, spray drying to obtain extract powder, adding an appropriate amount of auxiliary materials, mixing uniformly, granulating, and drying to obtain the traditional Chinese medicine composition.
2. The granule according to claim 1, wherein each 1000g of the granule comprises 750g of Glechomae herba, 375g of rhizoma Polygoni Cuspidati, 375g of herba Taraxaci, 562.5g of herba Artemisiae Scopariae, 562.5g of herba Lysimachiae Christinae, 187.5g of Saviae Miltiorrhizae radix, 187.5g of rhizoma Cyperi preparata, 187.5g of bupleuri radix, 187.5g of mume fructus, 187.5g of semen Cassiae, and appropriate adjuvants.
3. The jinqian dantong granule according to claim 1, wherein the xylitol accounts for 1 ~ 3% of the total weight of the granule.
4. The jinqian dantong granule according to claim 1, wherein xylitol accounts for 2% of the total weight of the granule.
5. A process for the preparation of the jinqian dantong granules according to any one of claims 1 ~ 4, which process comprises the steps of:
(1) respectively cutting the ten medicinal materials into middle blocks for later use;
(2) decocting Glechomae herba and herba Lysimachiae Christinae together with 8 ~ 10 times of water for 1 ~ 3 hr, filtering, decocting the residue with 6 ~ 8 times of water for 1 ~ 2 hr, filtering, and mixing the filtrates, wherein the extraction solvent is water containing 0.2 ~ 0.5.5% acetic acid;
(3) decocting the rest eight medicinal materials with 8 ~ 10 times of water for 1 ~ 3 hours, filtering, decocting the residue with 6 ~ 8 times of water for 1 ~ 2 hours, filtering, and mixing the filtrates;
(4) and (3) mixing the filtrates obtained in the steps (2) and (3), concentrating under reduced pressure to obtain fluid extract with a relative density of 1.05 ~ 1.10.10 at 55 ~ 60 ℃, spray drying to obtain extract powder, adding an appropriate amount of auxiliary materials, mixing uniformly, granulating, and drying to obtain the traditional Chinese medicine composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610387094.1A CN106038904B (en) | 2016-06-03 | 2016-06-03 | Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610387094.1A CN106038904B (en) | 2016-06-03 | 2016-06-03 | Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106038904A CN106038904A (en) | 2016-10-26 |
CN106038904B true CN106038904B (en) | 2019-12-20 |
Family
ID=57172738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610387094.1A Active CN106038904B (en) | 2016-06-03 | 2016-06-03 | Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106038904B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931302A (en) * | 2005-10-08 | 2007-03-21 | 周小明 | Chinese medicine composition for treating urethral calculus and gallstones and its prepn process |
CN101073659A (en) * | 2006-05-17 | 2007-11-21 | 赵赐安 | Chinese-herb-medicinal oral preparation for treating lithangiuria and cholecystolithiasis |
CN101380405A (en) * | 2008-10-13 | 2009-03-11 | 江苏晨牌药业有限公司 | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof |
CN101433649A (en) * | 2008-12-24 | 2009-05-20 | 广东万年青制药有限公司 | Composition for treating gall stone symptom |
-
2016
- 2016-06-03 CN CN201610387094.1A patent/CN106038904B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1931302A (en) * | 2005-10-08 | 2007-03-21 | 周小明 | Chinese medicine composition for treating urethral calculus and gallstones and its prepn process |
CN101073659A (en) * | 2006-05-17 | 2007-11-21 | 赵赐安 | Chinese-herb-medicinal oral preparation for treating lithangiuria and cholecystolithiasis |
CN101380405A (en) * | 2008-10-13 | 2009-03-11 | 江苏晨牌药业有限公司 | Traditional Chinese medicine preparation for treating cholelithiasis and preparation method thereof |
CN101433649A (en) * | 2008-12-24 | 2009-05-20 | 广东万年青制药有限公司 | Composition for treating gall stone symptom |
Also Published As
Publication number | Publication date |
---|---|
CN106038904A (en) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101612360B (en) | Medicine for treating hepatitis, hepatocirrhosis and liver cancer | |
CN102784363B (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
CN102210837A (en) | Medicament for treating acquired immune deficiency syndrome (AIDS) | |
KR102567235B1 (en) | Composition for the prevention and treatment of Inflammatory Bowl Disease | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
CN105614145A (en) | High-nutrient feed additive for meat pigeons and preparation method of feed additive | |
CN103933425A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
CN105267906A (en) | Compound chocolate Chinese herbal composition for treating and improving menstrual syndrome of females | |
CN106237247A (en) | A kind of Chinese medicine composition treating gynecological inflammation | |
CN105435197A (en) | Pharmaceutical composition for treating chronic lymphocytic thyroiditis and preparation method thereof | |
CN118434431A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
US11123388B2 (en) | Composition for preventing and treating inflammatory bowel disease | |
CN106038904B (en) | Lysimachia christinae and cholangiopsis cochinchinensis granule composition and preparation method thereof | |
CN105878655B (en) | Jinqianlitong granules for treating cholelithiasis | |
CN106421283A (en) | Traditional Chinese medicine ointment for treating skin diseases | |
CN105169102A (en) | Lung-clearing decoction | |
CN105891401B (en) | Money Hymecromone granular mass control method | |
CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
KR102246636B1 (en) | A composition for antiinflammation comprising natural extracts | |
CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes | |
CN108904649B (en) | Traditional Chinese medicine for treating urinary system infection and preparation method thereof | |
CN108186785A (en) | A kind of 12 taste Chinese medicine compositions for treating chronic pelvic inflammatory disease and its application | |
CN102188681B (en) | Traditional Chinese drug composition for treating pelvic inflammatory disease, preparation method, application thereof | |
CN109106877B (en) | Traditional Chinese medicine composition for preventing and treating mastitis caused by excessive heat evil of women in lactation period, preparation method and pharmaceutical preparation thereof | |
CN104623515A (en) | Drug for treating chronic pelvic inflammation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |